Category: Include on Menu
-
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade
Amgen (NASDAQ:AMGN) shares fell 4.7% to $416.88 in premarket trading as investors assessed the implications of a Phase III trial result from Novartis involving an experimental Lp(a)-lowering treatment, alongside a downgrade from BMO Capital. Novartis announced on September 4 that pelacarsen, an investigational treatment designed to reduce lipoprotein(a), did not reduce the risk of cardiovascular…
-
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
Dyne Therapeutics (NASDAQ:DYN) shares fell 31.0% to $16.76 in premarket trading, compared with a previous close of $24.28. No official company announcement confirming a reason for the share-price movement had been identified in the supplied information at the time of writing. Without such confirmation, the cause of the decline remains unclear. The stock was trading…
-
Sigma Lithium Shares Fall After Brazilian Court Orders Halt at Grota do Cirilo
Sigma Lithium (NASDAQ:SGML) shares fell nearly 12.0% in premarket trading after a Brazilian federal court ordered the suspension of environmental permits and mining operations at the company’s Grota do Cirilo complex in Minas Gerais. The injunction was issued on Friday by Judge Antonio Lucio Tulio de Oliveira Barbosa in connection with a civil lawsuit brought…
-
Bloom Energy Shares Rise After S&P 500 Inclusion Confirmed
Bloom Energy Corp (NYSE:BE) shares rose 5.1% to $265.70 in premarket trading after confirmation that the company will join the S&P 500 Index before the market opens on September 21. Inclusion in the benchmark means investment funds and exchange-traded funds that track the S&P 500 will need to adjust their holdings to reflect the revised…
-
Coyote Copper Builds Exploration Momentum at Copper Springs as Drilling Targets Potentially Large Porphyry System
Coyote Copper Mines (TSXV:CCMM) is advancing an ambitious exploration programme at its Copper Springs property, with recent geophysical work, surface mineralisation and a newly identified zone pointing towards the potential for a much larger copper system at depth. For copper explorers, one of the most important questions is whether a known historic resource represents the…
-
Novartis DM1 Drug Misses Primary Endpoint in Phase III Trial
Novartis (NYSE:NVS) said on Tuesday that its experimental treatment for myotonic dystrophy type 1, delpacibart etedesiran, did not meet the primary endpoint of a Phase III clinical trial. The global HARBOR study evaluated delpacibart etedesiran, also known as del-desiran, in approximately 150 people with myotonic dystrophy type 1, or DM1. The 54-week randomised, double-blind and…
-
Zim Integrated Shipping Shares Rise as Hapag-Lloyd Revises Takeover Proposal
Zim Integrated Shipping (NYSE:ZIM) shares rose as much as 5.5% in premarket trading on Tuesday after Hapag-Lloyd and FIMI said they planned to revise their proposed acquisition following discussions with Israeli officials. Hapag-Lloyd said on Monday that it was working with the Israeli government on changes to its proposed $4.2 billion cash acquisition of Zim…
-
Eaton Shares Rise After UBS Upgrade to Buy
Eaton (NYSE:ETN) shares rose 3.1% in premarket trading after UBS upgraded the power management company to Buy from Neutral and increased its price target to $515 from $450. UBS based its revised assessment on expectations for improved margins and earnings growth, forecasting that pricing measures and operational execution will contribute to a margin recovery beginning…
-
BioNTech Shares Fall After BMO Downgrade and Price Target Cut
BioNTech SE (NASDAQ:BNTX) shares fell 1.2% to $102.55 in premarket trading after BMO Capital downgraded the stock and reduced its price target. BMO lowered its rating on BioNTech from Outperform to Market Perform and cut its price target to $105 from $128. The firm cited lower global demand for COVID vaccines and an ongoing inventory…
-
SVRN Shares Rise 14.7% Premarket With No New Catalyst Identified
SVRN, Inc. (NASDAQ:SVRN) shares rose 14.7% to $10.40 in premarket trading, extending a period of wide price movements for the stock. No new company press release, earnings report or analyst action was identified in the supplied information as a direct catalyst for Tuesday’s advance. SVRN has traded between a 52-week low of $3.12 and a…